Published in Gene Ther on March 22, 2007
Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol (2008) 2.05
HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol (2010) 1.44
Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) (2010) 1.29
Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev (2011) 1.18
Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One (2008) 1.16
Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther (2011) 1.10
Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy (2010) 1.04
Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol (2009) 1.02
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets (2009) 1.01
Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther (2009) 1.00
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther (2012) 0.99
Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice. Infect Immun (2009) 0.91
Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther (2009) 0.90
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines (2007) 0.90
Noninvasive imaging of cell-mediated therapy for treatment of cancer. J Nucl Med (2008) 0.88
Involvement of ERK2 in traumatic spinal cord injury. J Neurochem (2010) 0.87
Gene therapy for cancer: present status and future perspective. Mol Cell Ther (2014) 0.87
Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors. J Biol Eng (2009) 0.87
Immunogenicity of targeted lentivectors. Oncotarget (2014) 0.86
Enhancement of dendritic cells as vaccines for cancer. Immunotherapy (2010) 0.86
Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice. PLoS One (2012) 0.85
Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. Gene Ther (2009) 0.83
Targeting lentiviral vectors for cancer immunotherapy. Curr Cancer Ther Rev (2011) 0.80
Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther (2009) 0.80
A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. Vaccine (2012) 0.79
Novel delivery approaches for cancer therapeutics. J Control Release (2015) 0.79
A dual-targeted lentiviral vector homing in on prostate bone metastases. Mol Ther (2007) 0.77
In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules (2014) 0.77
Sustained expression of insulin by a genetically engineered sertoli cell line after allotransplantation in diabetic BALB/c mice. Biol Reprod (2014) 0.77
Microfluidic models for adoptive cell-mediated cancer immunotherapies. Drug Discov Today (2016) 0.76
Limited transplantation of antigen-expressing hematopoietic stem cells induces long-lasting cytotoxic T cell responses. PLoS One (2011) 0.75
Selective killing of Smad4-negative tumor cells via a designed repressor strategy. Mol Pharmacol (2008) 0.75
Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes. PLoS One (2013) 0.75
Engineering cell-based therapies to interface robustly with host physiology. Adv Drug Deliv Rev (2016) 0.75
Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery. Gene Ther (2017) 0.75
Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth. Vaccine (2017) 0.75
CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med (1999) 6.06
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med (1998) 4.95
The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature (1991) 2.76
Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest (2000) 2.67
Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med (1992) 2.05
B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med (2000) 2.02
A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 1.91
Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods (1986) 1.73
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol (1994) 1.58
Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood (1992) 1.42
Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood (1999) 1.37
Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer (1997) 1.30
Role of CD8alpha+ and CD8alpha- dendritic cells in the induction of primary immune responses in vivo. J Leukoc Biol (1999) 1.30
Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther (2006) 1.30
Biclonal B-cell lymphoma. N Engl J Med (1984) 1.27
Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur J Immunol (1997) 1.27
Image-based point spread function implementation in a fully 3D OSEM reconstruction algorithm for PET. Phys Med Biol (2010) 1.24
Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol (1997) 1.24
Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood (1998) 1.22
Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol (1999) 1.16
Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene (2007) 1.15
Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol (1994) 1.14
Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood (1998) 1.12
A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res (2000) 1.12
Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. J Immunol (1984) 1.06
Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Clin Exp Immunol (1999) 1.05
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther (2005) 1.05
Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol (1989) 1.00
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood (2000) 1.00
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther (2012) 0.99
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol (1987) 0.98
CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation. Infect Immun (1999) 0.97
Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells. Diabetologia (2004) 0.96
Clonally related IgA- and IgE-secreting plasma cells in a myeloma patient. Eur J Haematol (2000) 0.95
Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol (1999) 0.94
Ly-1 (CD5), a membrane glycoprotein of mouse T lymphocytes and a subset of B cells, is a natural ligand of the B cell surface protein Lyb-2 (CD72). J Immunol (1992) 0.94
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol (2013) 0.94
CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost (1998) 0.93
Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer (1998) 0.93
IL-12 prevents neonatal induction of transplantation tolerance in mice. Eur J Immunol (1998) 0.92
CD45RO+ memory T cells but not CD45RA+ naive T cells can be efficiently activated by remote co-stimulation with B7. Int Immunol (1993) 0.91
Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res (1995) 0.91
Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol (1991) 0.89
CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. Scand J Immunol (2001) 0.89
Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. Infect Immun (1996) 0.88
Immunoglobulins D and M multiple myeloma variants are heavily mutated. Clin Cancer Res (1997) 0.88
Activation of murine T cells by bacterial superantigens requires B7-mediated costimulation. Cell Immunol (1995) 0.88
Autoimmune lymphoproliferative syndrome type III, an indefinite disorder. Leuk Lymphoma (2001) 0.87
Immunoglobulin VH gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumours with clinical features of human disease. Immunology (1998) 0.86
Co-stimulation lowers the threshold for activation of naive T cells by bacterial superantigens. Int Immunol (1995) 0.86
The effect of regularization in motion compensated PET image reconstruction: a realistic numerical 4D simulation study. Phys Med Biol (2013) 0.84
Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther (2006) 0.83
Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour. Leukemia (2001) 0.83
Lentiviral vectors: a versatile tool to fight cancer. Curr Mol Med (2013) 0.82
Inhibition of the CD40 pathway of monocyte activation by triazolopyrimidine. Clin Immunol (1999) 0.82
CD40 engagement induces monocyte procoagulant activity through an interleukin-10 resistant pathway. Eur J Immunol (1996) 0.81
Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. Adv Exp Med Biol (1993) 0.81
Production and characterization of bispecific single-chain antibody fragments. Mol Immunol (1995) 0.81
Extracting a respiratory signal from raw dynamic PET data that contain tracer kinetics. Phys Med Biol (2014) 0.81
Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens. Clin Exp Metastasis (1994) 0.80
Effects of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha on Trypanosoma cruzi trypomastigotes. Infect Immun (1998) 0.80
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer (1999) 0.80
In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J Immunol (1998) 0.80
Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis. Acta Neurol Belg (1999) 0.79
IFN-beta interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: selective inhibition of CD40-dependent interleukin-12 secretion. J Interferon Cytokine Res (1999) 0.79
Southern blot analysis in a case of Richter's syndrome. Evidence for a postrearrangement heavy chain gene deletion associated with the altered phenotype. Am J Clin Pathol (1991) 0.79
Cancer cell dissemination during curative surgery for colorectal liver metastases. Eur J Surg Oncol (2005) 0.79
Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther (1999) 0.79
Implementation and evaluation of a 3D one-step late reconstruction algorithm for 3D positron emission tomography brain studies using median root prior. Eur J Nucl Med Mol Imaging (2001) 0.79
Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy. Gene Ther (2013) 0.79
Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci (1992) 0.78
Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma. Cancer Res (1994) 0.78
Persistence of residual tumour cells after cytokine-mediated ex vivo expansion of mobilized CD34+ blood cells in multiple myeloma. Br J Haematol (1997) 0.78
The genetic variability of the VH genes in follicular lymphoma: the impact of the hypermutation mechanism. Br J Haematol (1999) 0.78
Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J Exp Med (1985) 0.78
Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. Br J Haematol (1999) 0.78
Enhanced 3D PET OSEM reconstruction using inter-update Metz filtering. Phys Med Biol (2000) 0.78
B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. Int J Cancer (2000) 0.77
Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng (1996) 0.77
Native soluble CD5 delivers a costimulatory signal to resting human B lymphocytes. Cell Immunol (1996) 0.77
The clonogenic precursor cell in multiple myeloma. Leuk Lymphoma (1995) 0.77
Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood (1996) 0.77
Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol (1991) 0.77
Bispecific antibody therapy of two murine B-cell lymphomas. Int J Cancer Suppl (1992) 0.77
Metastasis of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Dk antigens. Int J Cancer (1994) 0.76
Unexpected effects of viral interleukin-10-secreting dendritic cells in vivo: preferential inhibition of TH2 responses. Transplant Proc (2004) 0.76
Fighting with the enemy's weapons? the role of costimulatory molecules in HIV. Curr Mol Med (2011) 0.76
Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model. Cancer Immunol Immunother (1998) 0.76
Selective response of CD5+ B cell malignancies to activation of the CD72 antigen. Clin Immunol Immunopathol (1998) 0.76
Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol (1999) 0.75
Costimulation regulates the kinetics of interleukin-2 response to bacterial superantigens. Immunology (1996) 0.75
In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. J Hematother (1995) 0.75
Idiotypic vaccination as therapy for multiple myeloma. Semin Hematol (1999) 0.75
Cellular immunotherapy: a new avenue in internal medicine. Acta Clin Belg (1998) 0.75
The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency. Br J Haematol (1998) 0.75